Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis
- PMID: 22891307
- PMCID: PMC3435153
- DOI: 10.1073/pnas.1206037109
Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis
Abstract
Phase images obtained with gradient echo MRI provide image contrast distinct from T1- and T2-weighted images. It is commonly assumed that the local contribution to MRI signal phase directly relates to local bulk tissue magnetic susceptibility. Here, we use Maxwell's equations and Monte Carlo simulations to provide theoretical background to the hypothesis that the local contribution to MRI signal phase does not depend on tissue bulk magnetic susceptibility but tissue magnetic architecture--distribution of magnetic susceptibility inclusions (lipids, proteins, iron, etc.) at the cellular and subcellular levels. Specifically, we show that the regular longitudinal structures forming cylindrical axons (myelin sheaths and neurofilaments) can be locally invisible in phase images. Contrary to an expectation that the phase contrast in multiple sclerosis lesions should always increase in degree along with worsening of lesion severity (which happens for all known MR magnitude-based contrast mechanisms), we show that phase contrast can actually disappear with extreme tissue destruction. We also show that the phase contrast in multiple sclerosis lesions could be altered without loss of nervous system tissue, which happens in mild injury to the myelin sheaths or axonal neurofilaments. Moreover, we predict that the sign of phase contrast in multiple sclerosis lesions indicates the predominant type of tissue injury-myelin damage (positive sign) vs. axonal neurofilament damage (negative sign). Therefore, our theoretical and experimental results shed light on understanding the relationship between gradient echo MRI signal phase and multiple sclerosis pathology.
Conflict of interest statement
Conflict of interest statement: A.H.C. was a consultant for Teva Pharmaceutical Industries Ltd., Biogen Idec Inc., F. Hoffmann–La Roche Ltd., MedImmune, and Coronado Biosciences. A.H.C. also discloses support from Novartis Research, F. Hoffmann–La Roche Ltd Research, and the Sanofi-aventis Group.
Figures
References
-
- Abduljalil AM, Schmalbrock P, Novak V, Chakeres DW. Enhanced gray and white matter contrast of phase susceptibility-weighted images in ultra-high-field magnetic resonance imaging. J Magn Reson Imaging. 2003;18:284–290. - PubMed
-
- Zhong K, Leupold J, von Elverfeldt D, Speck O. The molecular basis for gray and white matter contrast in phase imaging. Neuroimage. 2008;40:1561–1566. - PubMed
-
- Marques JP, Maddage R, Mlynarik V, Gruetter R. On the origin of the MR image phase contrast: An in vivo MR microscopy study of the rat brain at 14.1 T. Neuroimage. 2009;46:345–352. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
